Oscar Health (OSCR) Revenue & Revenue Breakdown
Oscar Health Revenue Highlights
Latest Revenue (Y)
$11.70B
Latest Revenue (Q)
$2.99B
Oscar Health Revenue by Period
Oscar Health Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $11.70B | 27.50% |
| 2024-12-31 | $9.18B | 56.54% |
| 2023-12-31 | $5.86B | 42.11% |
| 2022-12-31 | $4.13B | 114.77% |
| 2021-12-31 | $1.92B | 225.78% |
| 2020-12-31 | $589.64M | 6.48% |
| 2019-12-31 | $553.78M | - |
Oscar Health generated $11.70B in revenue during NA 2025, up 27.50% compared to the previous quarter, and up 1984.50% compared to the same period a year ago.
Oscar Health Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $2.99B | 4.26% |
| 2025-06-30 | $2.86B | -5.98% |
| 2025-03-31 | $3.05B | 27.31% |
| 2024-12-31 | $2.39B | -1.27% |
| 2024-09-30 | $2.42B | 9.20% |
| 2024-06-30 | $2.22B | 3.57% |
| 2024-03-31 | $2.14B | 49.68% |
| 2023-12-31 | $1.43B | -0.58% |
| 2023-09-30 | $1.44B | -5.40% |
| 2023-06-30 | $1.52B | 3.57% |
| 2023-03-31 | $1.47B | 41.63% |
| 2022-12-31 | $1.04B | 1.88% |
| 2022-09-30 | $1.02B | -3.76% |
| 2022-06-30 | $1.06B | 4.67% |
| 2022-03-31 | $1.01B | 94.32% |
| 2021-12-31 | $520.33M | 12.58% |
| 2021-09-30 | $462.19M | -15.93% |
| 2021-06-30 | $549.75M | 41.43% |
| 2021-03-31 | $388.69M | 107.16% |
| 2020-12-31 | $187.63M | 40.75% |
| 2020-09-30 | $133.31M | -8.43% |
| 2020-06-30 | $145.57M | 18.23% |
| 2020-03-31 | $123.13M | - |
Oscar Health generated $2.99B in revenue during Q3 2025, up 4.26% compared to the previous quarter, and up 134.54% compared to the same period a year ago.
Oscar Health Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| OSCR | Oscar Health | $11.70B | $2.99B |
| OPCH | Option Care Health | $5.65B | $1.44B |
| ALHC | Alignment Healthcare | $3.95B | $993.70M |
| TMDX | TransMedics Group | $605.49M | $143.82M |
| HNGE | Hinge Health | $587.86M | $154.21M |
| KYMR | Kymera Therapeutics | $39.20M | $2.76M |
| NAMS | NewAmsterdam Pharma | $22.50M | $19.14M |
| AKRO | Akero Therapeutics | - | - |
| VKTX | Viking Therapeutics | - | - |
| IMVT | Immunovant | - | - |
| ACLX | Arcellx | - | $7.55M |